About Us
Avalyn is a clinical-stage biotech company developing inhaled therapies to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
Our goal is to deliver inhaled formulations of effective medicines directly to lung tissue, thus potentially enhancing efficacy and avoiding side effects associated with systemic drug delivery.
Our Pipeline
Our programs are championed by a leadership team with unparalleled expertise in the development of inhaled drugs. Avalyn’s pipeline includes two clinical stage programs, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), and a preclinical stage program, AP03 (a fixed dose combination of inhaled pirfenidone and nintedanib).
Latest News
March 25, 2026
Avalyn Announces Publication Demonstrating Correlation Between Imaging, Improved Lung Function, and Quality of Life with AP01 in Patients with Idiopathic Pulmonary Fibrosis
Read MoreMarch 23, 2026
Avalyn Announces First Patient Dosed in AURA Phase 2 Clinical Trial Evaluating AP02, Inhaled Nintedanib, for the Treatment of Idiopathic Pulmonary Fibrosis
Read MoreMarch 5, 2026
Avalyn Appoints Biopharmaceutical Industry Leader Kate Haviland to Board of Directors
Read MoreBiotechTV Featuring Avalyn's CEO
Avalyn’s CEO, Lyn Baranowski, describes the Company’s treatment approach for pulmonary fibrosis, where there is a large unmet need despite the three oral therapies available commercially. She explains how Avalyn’s nebulization method is designed to improve the substantial tolerability issues associated with current treatment options by directly targeting the lung through inhalation.